SDB-006

SDB-006
Legal status
Legal status	CA: Schedule II ; DE: Anlage II (Authorized trade only, not prescriptible) ; UK: Under Psychoactive Substances Act ;
Identifiers
	IUPAC name N-benzyl-1-pentyl-1H-indole-3-carboxamide;
CAS Number	695213-59-3 ;
PubChem CID	2227769;
ChemSpider	1665835;
Chemical and physical data
Formula	C21H24N2O
Molar mass	320.43 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NCC1=CC=CC=C1)C2=CN(CCCCC)C3=CC=CC=C32;

SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC₅₀ of 19 nM for human CB₂ receptors, and 134 nM for human CB₁ receptors.[1][2] It was discovered during research into the related compound SDB-001 which had been sold illicitly as "2NE1".[3] SDB-006 metabolism has been described in literature.[4]

References

Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" (PDF). ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M (January 2018). "The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs". Drug Testing and Analysis. 10 (7): 1099–1109. doi:10.1002/dta.2362. PMID 29350472.
Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.
Diao X, Carlier J, Scheidweiler KB, Huestis MA (July 2017). "In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology. 35 (2): 252–262. doi:10.1007/s11419-016-0350-9.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" (PDF). ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407.

[2] Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M (January 2018). "The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs". Drug Testing and Analysis. 10 (7): 1099–1109. doi:10.1002/dta.2362. PMID 29350472.

[3] Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.

[4] Diao X, Carlier J, Scheidweiler KB, Huestis MA (July 2017). "In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology. 35 (2): 252–262. doi:10.1007/s11419-016-0350-9.

SDB-006

See also

References